Pharmacokinetics, disposition, and metabolism of bicifadine in humans

Drug Metabolism and Disposition

Volumn 36, Issue 2, 2008, Pages 252-259

  Krieter, Philip A ^b   Gohdes, Mark ^a   Musick, Timothy J ^a   Duncanson, Frederick P ^b   Bridson, William E ^a  

^a Late Stage Developmental Services Covance Inc   (United States)

^b DOV Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICIFADINE; CARBON 14; CARBOXYLIC ACID; DOV 255828; DRUG METABOLITE; GLUCURONIDE; LACTAM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANALGESICS; BICYCLO COMPOUNDS, HETEROCYCLIC; FECES; HUMANS; MALE;

EID: 38749142158     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017871     Document Type: Article

References (15)

1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
2. Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, Nikiforuk A, Krawczyk M, Nowak G, et al. (2007) Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 321:1208-1225.
3. Cesura AM and Pletscher A (1992) The new generation of monoamine oxidase inhibitors. Prog Drug Res 38:171-297.
4. Compernolle F, Van Hees GP, Blanckaert N, and Heirwegh KP (1978) Glucuronic acid conjugates of bilirubin-IXalpha in normal bile compared with post-obstructive bile. Transformation of the 1-O-acylglucuronide into 2-, 3-, and 4-O-acylglucuronides. Biochem J 171:185-201.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
6. Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, and Krieter PA (2007) In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos 35:2232-2241.
7. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel Dekker, Inc., New York.
8. Hasegawa J, Smith PC, and Benet LZ (1982) Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab Dispos 10:469-473.
9. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, and Simmons RMA (2004) Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311:576-584.
10. Janssen FW, Kirkman SK, Fenselau C, Stogniew M, Hofmann BR, Young EM, and Ruelius HW (1982) Metabolic formation of N- and O-glucuronides of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid. Rearrangement of the 1-O-acyl glucuronide. Drug Metab Dispos 10:599-604.
11. Musick TJ, Gohdes M, Duffy A, Erickson DA, and Krieter PA (2008) Pharmacokinetics, disposition, and metabolism of the analgesic bicifadine in the mouse, rat, and monkey. Drug Metab Dispos 36:241-251.
12. Riff D, Huang N, Czobor P, and Stern W (2006) A five-day, multi-center, randomized, placebo-controlled, double-blind, efficacy and safety study of bicifadine and tramadol versus placebo in the treatment of postoperative bunionectomy pain. J Pain 7 (Suppl 2):S40.
13. Semenchuck MR, Sherman S, and Davis B (2001) Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57:1583-1588.
14. Sindrup SH, Otto M, Finnerup NB, and Jensen TS (2005) Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 96:399-409.
15. Stern W, Czobor P, Stark J, and Krieter P (2005) Relationship between plasma bicifadine levels and analgesic effect in a dental pain model, in Abstracts: 11th World Congress on Pain; 2005 Aug 21-26; Sydney, Australia; pp 111, International Association for the Study of Pain, Seattle.